Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com

Stock analysts at StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a report released on Saturday. The firm set a “sell” rating on the stock.

A number of other research firms have also recently commented on SYRS. Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. HC Wainwright restated a “neutral” rating and set a $1.00 price objective (down previously from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $3.33.

Syros Pharmaceuticals Price Performance

Shares of NASDAQ:SYRS opened at $0.18 on Friday. Syros Pharmaceuticals has a 1 year low of $0.16 and a 1 year high of $7.96. The business’s 50-day moving average is $0.23 and its 200-day moving average is $1.84. The company has a market capitalization of $4.70 million, a price-to-earnings ratio of -0.06 and a beta of 1.31.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.08. During the same period in the prior year, the firm earned ($1.35) EPS. Analysts anticipate that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Insider Activity

In related news, Director Nancy A. Simonian sold 134,713 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $0.27, for a total transaction of $36,372.51. Following the completion of the transaction, the director now owns 41,070 shares in the company, valued at approximately $11,088.90. This represents a 76.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 12.26% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Syros Pharmaceuticals

An institutional investor recently raised its position in Syros Pharmaceuticals stock. Exome Asset Management LLC boosted its stake in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by 87.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 298,575 shares of the company’s stock after purchasing an additional 139,400 shares during the quarter. Exome Asset Management LLC owned approximately 1.11% of Syros Pharmaceuticals worth $642,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.